We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
Read MoreHide Full Article
Key Takeaways
AbbVie won EU approval for Tepkinly R2 in adult patients with R/R FL after prior therapy.
ABBV's phase III study showed a 79% lower risk of progression or death versus R2 alone, with higher responses.
AbbVie and Genmab continue to advance epcoritamab across blood cancers through late-stage clinical studies.
AbbVie (ABBV - Free Report) announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed or refractory follicular lymphoma (R/R FL) indication. The EC approved the drug in combination with rituximab and lenalidomide (Tepkinly+R2) for adult patients with R/R FL after at least one line of systemic therapy.
The approval represents Tepkinly's third indication in the European Union (EU) and marks the first EU approval of a bispecific-based, chemotherapy-free therapy for second-line relapsed or refractory follicular lymphoma.
To remind investors, ABBV markets epcoritamab under the brand name Epkinly in the United States and Japan, and as Tepkinly in the EU.
Tepkinly is already approved as monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma and R/R FL after two or more lines of systemic therapy in the EU.
The FDA approved Epkinly in combination with rituximab and lenalidomide for a similar indication in the United States in November 2025.
Year to date, ABBV shares have rallied 11.5% compared with the industry’s 13.8% growth.
Image Source: Zacks Investment Research
ABBV's Tepkinly Combo EU Nod Backed by Phase III Study
The EU approval is based on data from the pivotal phase III EPCORE FL-1 study, which demonstrated that Tepkinly+R2 significantly improved outcomes compared to the standard-of-care R2 alone in second-line patients with R/R FL. The combination reduced the risks of disease progression or death by 79% and achieved higher overall and complete response rates versus R2 alone. Its safety profile was consistent with the known profiles of the previous individual therapies, with no new safety signals identified.
The most common adverse events included neutropenia, rash, infections, fatigue, diarrhea, COVID-19 and cytokine release syndrome, while serious adverse events occurred in 44% of patients.
Follicular lymphoma is a slow-growing type of B-cell non-Hodgkin lymphoma and the second most common subtype of the disease. Although treatment can induce remission, FL remains incurable, with many patients experiencing relapses and requiring additional therapies over time. The disease is more prevalent in European populations than in non-European populations.
AbbVie has partnered with Genmab (GMAB - Free Report) to jointly develop epcoritamab under the companies' oncology collaboration agreement. While both companies share commercialization rights in the United States and Japan, AbbVie is responsible for commercialization in other global markets. AbbVie and Genmab continue to advance their global development and regulatory expansion while evaluating the therapy as a monotherapy and in combination regimens across multiple hematologic malignancies through several late-stage clinical studies.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents per share. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 8% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, loss per share estimates for Amarin have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 12.5% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
View the Zacks #1 Rank List
Image: Bigstock
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
Key Takeaways
AbbVie (ABBV - Free Report) announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed or refractory follicular lymphoma (R/R FL) indication. The EC approved the drug in combination with rituximab and lenalidomide (Tepkinly+R2) for adult patients with R/R FL after at least one line of systemic therapy.
The approval represents Tepkinly's third indication in the European Union (EU) and marks the first EU approval of a bispecific-based, chemotherapy-free therapy for second-line relapsed or refractory follicular lymphoma.
To remind investors, ABBV markets epcoritamab under the brand name Epkinly in the United States and Japan, and as Tepkinly in the EU.
Tepkinly is already approved as monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma and R/R FL after two or more lines of systemic therapy in the EU.
The FDA approved Epkinly in combination with rituximab and lenalidomide for a similar indication in the United States in November 2025.
Year to date, ABBV shares have rallied 11.5% compared with the industry’s 13.8% growth.
Image Source: Zacks Investment Research
ABBV's Tepkinly Combo EU Nod Backed by Phase III Study
The EU approval is based on data from the pivotal phase III EPCORE FL-1 study, which demonstrated that Tepkinly+R2 significantly improved outcomes compared to the standard-of-care R2 alone in second-line patients with R/R FL. The combination reduced the risks of disease progression or death by 79% and achieved higher overall and complete response rates versus R2 alone. Its safety profile was consistent with the known profiles of the previous individual therapies, with no new safety signals identified.
The most common adverse events included neutropenia, rash, infections, fatigue, diarrhea, COVID-19 and cytokine release syndrome, while serious adverse events occurred in 44% of patients.
Follicular lymphoma is a slow-growing type of B-cell non-Hodgkin lymphoma and the second most common subtype of the disease. Although treatment can induce remission, FL remains incurable, with many patients experiencing relapses and requiring additional therapies over time. The disease is more prevalent in European populations than in non-European populations.
AbbVie has partnered with Genmab (GMAB - Free Report) to jointly develop epcoritamab under the companies' oncology collaboration agreement. While both companies share commercialization rights in the United States and Japan, AbbVie is responsible for commercialization in other global markets. AbbVie and Genmab continue to advance their global development and regulatory expansion while evaluating the therapy as a monotherapy and in combination regimens across multiple hematologic malignancies through several late-stage clinical studies.
ABBV’s Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) and Amarin Corporation (AMRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents per share. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 8% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, loss per share estimates for Amarin have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 12.5% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.